Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc.: Pioneering Novel Cancer Therapies
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company dedicated to transforming the oncology treatment landscape through innovative therapies. Headquartered in Newton, Massachusetts, Karyopharm is at the forefront of developing and commercializing Selective Inhibitor of Nuclear Export (SINE) compounds, a groundbreaking approach targeting nuclear export dysregulation—a critical mechanism in cancer progression. Since its founding, the company has been committed to addressing high unmet medical needs in oncology.
Core Technology and Lead Product: XPOVIO® (Selinexor)
Karyopharm's flagship product, XPOVIO® (selinexor), is the first FDA-approved oral exportin 1 (XPO1) inhibitor. This first-in-class therapy selectively binds to and inhibits XPO1, a protein responsible for exporting tumor suppressor proteins from the nucleus, thereby restoring their function and inducing cancer cell death. XPOVIO has received regulatory approval for multiple oncology indications, including:
- In combination with Velcade® (bortezomib) and dexamethasone for adult patients with multiple myeloma after at least one prior therapy.
- In combination with dexamethasone for heavily pretreated multiple myeloma patients.
- As a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy.
Additionally, XPOVIO (marketed as NEXPOVIO® in certain regions) has gained regulatory approvals in numerous countries, including Europe, the United Kingdom, China, South Korea, and Canada, through strategic partnerships with global pharmaceutical companies.
Pipeline and Research Focus
Karyopharm is advancing a robust pipeline of clinical trials targeting high unmet-need cancer indications. Key areas of focus include:
- Endometrial Cancer: The Phase 3 XPORT-EC-042 trial evaluates selinexor as a maintenance therapy for TP53 wild-type advanced or recurrent endometrial cancer.
- Myelofibrosis: The Phase 3 SENTRY trial explores selinexor in combination with ruxolitinib for JAK inhibitor-naïve patients.
- Other Indications: Ongoing studies include multiple myeloma and additional hematologic malignancies.
Revenue Streams and Global Presence
Karyopharm primarily generates revenue through U.S. sales of XPOVIO, complemented by licensing and milestone payments from international partners. Its strategic collaborations with companies like Menarini and Antengene facilitate the global distribution of its products, expanding its reach to markets in Asia, Europe, and beyond.
Challenges and Competitive Landscape
Operating in the highly competitive oncology pharmaceutical industry, Karyopharm faces challenges such as regulatory complexities, competition from established therapies, and the financial burden of clinical trials. Key competitors include major pharmaceutical companies developing treatments for similar indications. However, Karyopharm's unique focus on nuclear export dysregulation and its first-mover advantage with XPOVIO position it as a distinctive player in the market.
Commitment to Patients and Innovation
Driven by a mission to improve the lives of cancer patients, Karyopharm combines scientific innovation with a patient-centric approach. Its dedication to pioneering therapies addressing critical medical needs underscores its role as a transformative force in oncology.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that its Phase 3 SIENDO study of XPOVIO (selinexor) for advanced endometrial cancer passed a planned interim futility analysis. The Data and Safety Monitoring Board recommended continuing the study without protocol modifications. The study features 248 patients randomized to receive either XPOVIO or placebo, aiming to demonstrate a hazard ratio of 0.6 for progression-free survival. Top-line data is expected in the second half of 2021. XPOVIO has previously received FDA approvals for multiple myeloma and diffuse large B-cell lymphoma.
Karyopharm Therapeutics (KPTI) announced positive results from the Phase 3 SEAL study for XPOVIO® (selinexor) in treating advanced unresectable dedifferentiated liposarcoma at CTOS 2020. The study demonstrated a statistically significant increase in median progression-free survival (PFS) for patients treated with XPOVIO (2.83 months) compared to placebo (2.07 months, HR=0.70; p=0.023). XPOVIO also achieved a 30% reduced risk of disease progression or death. A New Drug Application to the FDA is anticipated in Q1 2021, marking XPOVIO as a potential first oral therapy for this cancer type.
Karyopharm Therapeutics (KPTI) announced results from the Phase 3 BOSTON study, published in The Lancet, which evaluated XPOVIO in combination with Velcade® and low-dose dexamethasone for relapsed or refractory multiple myeloma. The once-weekly regimen (SVd) showed a 30% reduction in disease progression or death risk compared to the standard regimen (Vd). Key metrics included a 47% improvement in progression-free survival and a 76.4% overall response rate. The FDA accepted a supplemental New Drug Application for XPOVIO with a PDUFA date of March 19, 2021.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, will have CEO Michael Kauffman participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, at 1:45 p.m. ET. Investors can access the live webcast on the company's investor site, with a replay available for 90 days after the event. Karyopharm specializes in novel drugs targeting nuclear export, notably XPOVIO® (selinexor), which received FDA approval for multiple myeloma and lymphoma. For more details, visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the selection of twenty-one abstracts for virtual presentation at the ASH 2020 Annual Meeting, scheduled for December 5-8, 2020. Noteworthy presentations will include updated clinical data for XPOVIO (selinexor) in combination therapies for multiple myeloma and lymphoma. Key studies from the STOMP and BOSTON trials will be highlighted, showcasing encouraging response rates and safety profiles. An investor event will be held to discuss the clinical program and ASH data.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that the Compensation Committee granted stock options to purchase 86,900 shares to 13 new employees on October 30, 2020. The options have an exercise price of $14.82 per share, equivalent to Karyopharm's closing stock price on that date. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly. Immediate full exercise is possible if employment is terminated for 'good reason' or without 'cause' within a year of a change in control event.
Karyopharm Therapeutics (KPTI) reported Q3 2020 financial results, achieving $21.3 million in net product sales, a 15% increase from Q2, primarily driven by new multiple myeloma and DLBCL patient starts. The company presented positive top-line results from the Phase 3 SEAL study, showing XPOVIO's efficacy in treating dedifferentiated liposarcoma, with plans to submit a New Drug Application to the FDA in Q1 2021. Karyopharm expects ongoing revenue from XPOVIO to support operations through mid-2022, despite a net loss of $53.5 million for the quarter.
Karyopharm Therapeutics (Nasdaq: KPTI) reported positive top-line results from the Phase 3 SEAL study, indicating that XPOVIO® (selinexor) significantly increases progression-free survival (PFS) in patients with advanced unresectable dedifferentiated liposarcoma, showing a 30% reduction in disease progression risk compared to placebo. The study involved approximately 285 patients, and results will be presented at the CTOS Annual Meeting on November 20, 2020. Karyopharm plans to submit a New Drug Application to the FDA in Q1 2021, potentially positioning XPOVIO as the first oral, non-chemotherapy treatment for this condition.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will announce its third quarter 2020 financial results on November 2, 2020. A conference call led by the management team will take place at 4:30 p.m. ET that same day to discuss the results and company updates. The company focuses on developing innovative cancer therapies, including its lead product XPOVIO (selinexor), which has received FDA approvals for multiple myeloma and diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor is also under review in Europe.
MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) has chosen its Transparency Solution to meet state and federal reporting regulations. Launched in October 2020, this SaaS-based platform collects, validates, and reports transfers of value to ensure compliance with transparency laws. Karyopharm sought advanced technology and advisory services from MediSpend to manage evolving regulations effectively. Karyopharm is known for its innovative cancer therapies, including the FDA-approved drug XPOVIO®.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics Inc.'s core focus?
What is XPOVIO® (selinexor)?
How does Karyopharm generate revenue?
What are Karyopharm's key clinical trials?
What makes Karyopharm unique in the oncology space?
